Clinical trials: Cancer of Bladder
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Urothelial Cancer, Urinary Bladder Neoplasms
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer.
- Trial name
- NCT07566156
- Testing
- Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 390 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Kidney Cancer, Bladder Cancer
A Study of a Side Effects and Resource Navigation Program for People With Cancer
The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care.
- Conditions
- Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT07646847
- Testing
- Immunotherapy CARE Program
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Transurethral En Bloc Versus Standard Resection of Bladder Tumour
Conventionally, transurethral standard resection (SR) of bladder tumour is performed in a piecemeal manner. Transurethral en bloc resection (EBR) has been described as an alternate surgical technique in bladder tumour resection.
- Trial name
- NCT02993211
- Testing
- Bipolar transurethral standard resection, Bipolar transurethral en bloc resection
- Where
- 13 sites in Hong Kong
- Volunteers
- 350 people
- Sponsor
- Chinese University of Hong Kong
Urinary Bladder Neoplasms
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Background: Non-muscle-invasive bladder cancer is in the early stages. But it usually comes back after treatment. The drugs Vicineum and Durvalumab may help the immune system find and destroy cancer cells.
- Trial name
- NCT03258593
- Testing
- Durvalumab, Vicineum, Acetaminophen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Hyperthermia
Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT
This is a prospective single-arm pilot study investigating the safety and feasibility of giving hyperthermic intravesical chemotherapy immediately following transurethral resection of bladder tumour.
- Conditions
- Bladder Cancer, Hyperthermia, Chemotherapy Effect
- Trial name
- I-HIVEC (NCT03689478)
- Testing
- Hyperthermic intravesical chemotherapy
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Bladder Cancer, Bladder Neoplasm
Transurethral Modified En Bloc Resection For Large Bladder Tumours.
Modified en bloc resection is a hybrid technique involving piecemeal resection of the exophytic part of the bladder tumour, followed by en bloc resection of the tumour base.
- Conditions
- Bladder Cancer, Bladder Neoplasm, Bladder Tumor
- Trial name
- NCT04081246
- Testing
- Bipolar transurethral modified en bloc resection of bladder tumour
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Bladder Cancer
The Global En Bloc Resection of Bladder Tumour Registry
The study aims to collect data on ERBT globally in order to clarify its role in the management of bladder cancer over a 5-year observation period.
- Trial name
- NCT04934540
- Testing
- En bloc resection of bladder tumour
- Where
- 2 sites in Hong Kong
- Volunteers
- 5,000 people
- Sponsor
- Chinese University of Hong Kong
Bladder Cancer
Bladder Washing Cytology for Detection of Urothelial Carcinoma Using Catheter or Flexible Cystoscope: Which is Better?
Urine cytology can be collected with spontaneous urine or by washing the bladder. It is commonly accepted among urologist that instrumental bladder washing is the method of choice.
- Trial name
- BWash (NCT05643807)
- Testing
- Flexible cystoscopy, Urinary catheter
- Where
- Switzerland
- Volunteers
- 414 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Low-grade NMIBC, FGFR Gene Amplification
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
- Conditions
- Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration
- Trial name
- SURF302 (NCT06995677)
- Testing
- TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- Tyra Biosciences, Inc
Bladder Tumors, Bladder Tumor
Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial
This phase I study evaluates intravesical calcium electroporation (CaEP) with a new transurethral electrode. The study is primarily designed to assess the safety of CaEP and secondarily, to preliminary explore the efficacy in…
- Conditions
- Bladder Tumors, Bladder Tumor, Urothelial Carcinoma (UC), Urothelial Carcinoma Bladder
- Trial name
- CALCIFER (NCT07555769)
- Testing
- Calcium electroporation, Intratumoral calcium injection, Transurethral electroporation
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Juan Luis Vásquez
Bladder Cancer
Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC
This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.
- Trial name
- NCT07724886
- Testing
- Conventional Transurethral Resection of Bladder Tumour, Transurethral En Bloc Resection of Bladder Tumour
- Where
- 2 sites in Hong Kong
- Volunteers
- 732 people
- Sponsor
- Chinese University of Hong Kong
Metastatic Urothelial Carcinoma, Urothelial Cancer
A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different Histologies
Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine.
- Conditions
- Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma
- Trial name
- NCT07897669
- Volunteers
- 5,122 people
- Sponsor
- Pfizer
NMIBC, TCC
1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors
to compare pathological and oncological outcomes of TURBT versus ERBT in patients with bladder tumors sizes >2.5cm.
- Trial name
- NCT07898033
- Testing
- En Bloc Resection of Bladder Tumor, Trans Urethral Resection of Bladder Tumor
- Where
- Israel
- Volunteers
- 136 people
- Sponsor
- dmitry enikeev
Malignant Neoplasms, Hereditary Neoplastic Syndromes
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI.
- Conditions
- Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
- Trial name
- NCT00026884
- Where
- United States
- Volunteers
- 5,950 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Metastatic Bladder Cancer
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
The purpose of this study is to test the safety of the study drug, atezolizumab, when combined with the standard chemotherapy drugs, gemcitabine and cisplatin (or GC).
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma
- Trial name
- NCT02989584
- Testing
- Atezolizumab, Gemcitabine, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 54 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma
Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
This phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into the deep muscle of the bladder wall (muscle-invasive) or urothelial cancer that has spread from where it…
- Conditions
- Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma
- Trial name
- AMBASSADOR (NCT03244384)
- Testing
- Biospecimen Collection, Clinical Observation, Computed Tomography
- Where
- 914 sites in United States, Guam
- Volunteers
- 739 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
Single-arm, open-label window-of-opportunity trial of neoadjuvant Abemaciclib in 20 patients, with tumor tissue obtained as standard of care at tumor resection (pre-Abemaciclib) and cystectomy (post-Abemaciclib)
- Trial name
- CLONEVO (NCT03837821)
- Testing
- Abemaciclib
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment.
- Conditions
- Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
- Trial name
- NCT04164082
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 390 sites in United States, Guam and 1 more
- Volunteers
- 161 people
- Sponsor
- National Cancer Institute (NCI)